Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
|Articles|January 11, 2013
Unraveling the Layers: IDNs, ACOs, and the Future of Healthcare Integration
Author(s)HRA
This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.
Advertisement
This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.
- The webinar covers key issues in healthcare integration, including: the changing healthcare landscape and the need for integration.
- Defining the IDN, ACO, and PCMH
- Why IDN, ACO, and PCMH are important customer segments and how they are evolving
- How IDNs, ACOs, and PCMHs intersect and where is it going in the future
- The current and future role of the payor in an integrated environment
- The impact of Healthcare Reform on integration
- Identifying the customer, and appropriate contracting strategies.
Advertisement
Related to this article
The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
SurVaxM missed the SURVIVE trial OS end point in newly diagnosed glioblastoma, whereas a subgroup of patients 65 or younger had significantly improved OS.
The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.
The FDA has approved atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery.
The FDA approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with high-grade papillary-only tumors.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma
3
VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer
4
FDA Receives NDA Resubmission for Rivoceranib Plus Camrelizumab in Frontline Unresectable or Metastatic HCC
5